Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
40 participants
INTERVENTIONAL
2009-01-31
2011-10-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
MKTP treatment
subject will undergo MKTP
Melanocyte-keratinocyte transplantation procedure (MKTP)
skin pigment cells are taken from areas of normal skin and placed on areas of that same person's body which have lost their color.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Melanocyte-keratinocyte transplantation procedure (MKTP)
skin pigment cells are taken from areas of normal skin and placed on areas of that same person's body which have lost their color.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Have a diagnosis of vitiligo with no news lesions or growth of old lesions in the past 6 months
3. Be able to understand the requirements of the study, the risks involved, and be able to sign the informed consent form
4. Agree to follow and undergo all study-related procedures
Exclusion Criteria
2. Patients with a history of developing vitiligo or keloids at sites of trauma
3. Patients self-reported as having HIV or Hepatitis C
4. Patients self-reported as having uncontrolled Diabetes Mellitus
5. The investigator feels the patient should not participate in the study for any reason
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Henry Ford Health System
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Iltefat Hamzavi
Dermatologist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Iltefat H Hamzavi, MD
Role: PRINCIPAL_INVESTIGATOR
Henry Ford Health Systems Dermatology Department
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Henry Ford Medical Center, New Center One
Detroit, Michigan, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Mulekar SV. Long-term follow-up study of segmental and focal vitiligo treated by autologous, noncultured melanocyte-keratinocyte cell transplantation. Arch Dermatol. 2004 Oct;140(10):1211-5. doi: 10.1001/archderm.140.10.1211.
Mulekar SV. Long-term follow-up study of 142 patients with vitiligo vulgaris treated by autologous, non-cultured melanocyte-keratinocyte cell transplantation. Int J Dermatol. 2005 Oct;44(10):841-5. doi: 10.1111/j.1365-4632.2005.02226.x.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
5385
Identifier Type: -
Identifier Source: org_study_id